Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 15/20 | 0.50 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524822 | 0.92 | JAK3 (0.46) | FLT4KDRJAK3JAK2PTK2 | |
| SCHEMBL14576576 | 0.88 | PTK2 (0.51) | FLT4KDRJAK3JAK2PTK2 | |
| SCHEMBL15524688 | 0.86 | FLT4 (0.63) | FLT4KDRPTK2 | |
| SCHEMBL15588222 | 0.85 | PTK2 (0.43) | FLT4JAK3JAK2PTK2 | |
| SCHEMBL14576814 | 0.85 | PTK2 (0.48) | FLT4KDRJAK3JAK2PTK2 | |
| SCHEMBL15524130 | 0.85 | PTK2 (0.41) | FLT4JAK3JAK2PTK2 | |
| SCHEMBL14644047 | 0.85 | CCND3 (0.51) | JAK3JAK2PTK2 | |
| SCHEMBL15524261 | 0.85 | CCNA2 (0.45) | FLT4PTK2 | |
| SCHEMBL15506929 | 0.85 | FLT4 (0.59) | FLT4KDRJAK3JAK2PTK2 | |
| SCHEMBL15506724 | 0.85 | FLT4 (0.61) | FLT4KDRJAK3JAK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | GOT1, AADAT, ADH1A | FLT4 4643/4885KDR 4629/4885JAK3 2134/4885 |
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885JAK3 26/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | FLT4 1/4885KDR 3/4885JAK3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.